⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 22, 2021Antimicrobial Agents and ChemotherapyOpen Access

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

View Full Paper

Ask AI

Bookmark

Share

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2021 study studied this question.

synapsesocial.com/papers/6aab87ec7347306ad5268637 https://doi.org/10.1128/aac.01990-21

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)2018 · 194 citations
2Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)2020 · 109 citations
3In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-20152018 · 156 citations
4In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria2019 · 189 citations
5Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae2018 · 73 citations